Search

Thursday 25 July 2024

What’s Hot – ACW, LRV, EGR, LV1, LYN & SPR

What’s Hot, Not & Doing
Brought to you by TSN Contributor & Wealth Advisor Nick Kelso

What’s Hot – ACW, LRV, EGR, LV1, LYN & SPR
What’s Not – IMM

What’s Hot
ACW – Actinogen Medical Limited today closed up 35% to finish at 6.2c on $2m stock traded. There was no news out today but on Wednesday they announced a positive Xanamem phase 2a biomarker trial was published in the Journal of Alzheimer’s Disease (AD).

The biomarker trial was conducted as a stand-alone, prospective, double-blind trial using newly generated plasma biomarker data and clinical data on file from the XanADu phase 2a trial in patients with a clinical diagnosis of mild AD.

In the 34 patients with elevated pTau181 a potentially large and clinically meaningful treatment effect compared to placebo was seen in the CDR-SB and positive trends were observed in a neuropsychological test battery of cognition.

LRV – Larvotto Resources Limited today closed up 20% to finish at 12c on $690k stock traded. The reason they were up today was because they announced an exploration update for its Hillgrove Project located in NSW.

An exploration target has been delineated at Hillgrove with potential mineralisation located directly below areas of the current mineral resources.

The exploration target of between approximately 670k-1.08Moz AuEq, ranging between approximately 7.4-9.46 g/t AuEq.

EGR – EcoGraf Limited today closed up 14% to finish at 12c on $130k stock traded. There was no news out today but roughly a month ago they announced a binding agreement was signed with AngloGold Ashanti for a farm-in agreement at its Golden Eagle gold project located in Tanzania.

AngloGold Ashanti (US$10.5b market cap) is an independent, global gold mining company with a diverse, high-quality portfolio of operations, projects and exploration activities across ten countries on four continents.

AngloGold can earn up to a 70% interest by spending US$8.9m (approx. A$13.4m) over five years on the licences, EGR will then have the option to maintain its 30% or dilute to a gross revenue royalty.

LV1 – Live Verdure Limited today closed up another 12% to finish at 52c on $380k stock traded. There was no news out today but on Wednesday they announced the formation of a new AI Category Advisory Council and the appointment of its initial members.

This council aligns with their ongoing efforts to integrate AI across all facets of their operations, driving efficiency, enhancing customer engagement, and unlocking new revenue streams by extending the AI solutions to other categories.

The council will collaborate with the Board and the Decidr executive team to develop and refine the company’s overall AI organisational strategy and priorities, focusing on AI category positioning, structuring and monetisation.

LYN – Lycaon Resources Limited today closed up 11% to finish at 25.5c on $220k stock traded. There was no news out today but last week they announced a heritage survey was scheduled for its Stansmore West Arunta Project located in WA.

The heritage survey is scheduled to commence on the 11th of July with the intent to clear targets for ground-based geophysics and drilling within Q3 this year.

The Stansmore Niobium-REE Project extends over 173km² and is approximately 90km north of WA1 Resources’ (WA1.asx) Luni and P2 discoveries.

SPR – Spartan Resources Limited today closed up 11% to finish at 98.5c on $8m stock traded. There was no news out today but yesterday they announced Ramelius Resources (RMS.asx) had purchased 98.5m shares (8.9% interest) in Spartan.

Subject to the actions of Spartan or any third party, Ramelius has no current intention to acquire control or make a takeover offer for Spartan.

The purchase was made at 89c which represented an 8.5% premium to the last closing share price of 82c.

Spartan recently announced drill results from the Pepper Gold Prospect within its Dalgaranga Gold Project in WA, highlights included intercepts of up to 19.67m @ 19.43g/t gold from 765.33m.

What’s Not
IMM – Immutep Limited today closed down 12% to finish at 29.5c on $9m stock traded. The reason they were down today was because they announced topline results from the TACTI-003 Phase IIb trial.

The trial was evaluating eftilagimod alfa (efti) in combination with MSD’s (Merck & Co) anti-PD-1 therapy KEYTRUDA (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC).

The results revealed that the combination therapy significantly outperformed KEYTRUDA monotherapy across various levels of PD-L1 expression.

Notably, patients with high PD-L1 expression (CPS >20) exhibited an overall response rate (ORR) of 31.0%, compared to 18.5% with KEYTRUDA alone in the randomised Cohort A of the trial.

Immutep will now discuss potential options with regulatory agencies for metastatic 1L HNSCC patients.

Rats Rant – IMPORTANT INFORMATION
The idea of this report is to be informative and hopefully point out some stocks that you wouldn’t ordinarily have seen during the day, maybe even have a laugh too.This report IS NOT personal advice. Sanlam Private Wealth Pty Ltd DOES NOT PROVIDE personal advice, Sanlam Private Wealth provides General Financial Product Advice.All advice included in The Rat’s Rant is General Advice. Please refer to the General Advice Warning. The views expressed in this report are my views and may not necessarily reflect the same views as Sanlam Private Wealth.It is very important to refer to the ASX website for information on any companies / stock that are contained in this report and as always please consult your financial adviser before acting.

Important Notice
Rat Consulting Pty Ltd (ABN 81 148 181 588 ) Authorised Representative (No 001281456) of Sanlam Private Wealth Ltd (ABN 18 136 960 775) holder of Australian Financial Services Licence (AFSL 337 927).

Free stock updates

Subscribe to receive the latest stock news, CEO interviews, expert insights, events and offers directly into your inbox